Nanjing Puenrui Biotechnology
Oncology precision medicine R&D and CRO services.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | CNY200m | Series B | |
| Total Funding | 000k | ||
Nanjing Puenrui Biotechnology Co., Ltd. is a high-tech enterprise specializing in precision oncology diagnostics. Founded in 2015 by founder and chairman Zhu Yanping, the company is recognized as one of the first institutions in China to conduct in-vivo pharmacodynamic testing for individualized treatment. The firm serves over 100 domestic and international pharmaceutical companies with CRO services and provides individualized precision treatment services for cancer patients. Its business model centers on offering a one-stop service platform for tumor efficacy evaluation using its proprietary technologies and providing R&D for companion diagnostics.
Puenrui's core offering is its Patient-Derived Tumor Xenograft (PDTX) model platform, which includes patented technologies like FastPDTX® and HIS-PDTX (a dual-humanized model). These models simulate clinical trials in mice to assess the effectiveness of anti-tumor drugs, offering a faster and more precise method for drug sensitivity testing. The company has established a substantial biobank and database containing pharmacodynamic phenotype data, clinical phenotype information, and lifeomics data from living tumor tissues. This resource supports the development of companion diagnostic kits for anti-tumor drugs and new drug target discovery.
Financially, Puenrui has secured significant backing from various government and venture capital funds, including the National Science and Technology Achievement Transformation Guidance Fund. The company has completed multiple funding rounds, including a Series A in January 2019 and a Series B in December 2021 that raised over 200 million RMB. These funds are allocated to expanding the tumor biobank, enhancing CRO service capabilities, and accelerating the development and manufacturing of IVD test kits in its GMP-compliant facility. The company has received numerous accolades, including the title of "Nanjing Unicorn Cultivation Enterprise" in 2022.
Keywords: precision oncology, PDX models, cancer diagnostics, pharmacodynamics, companion diagnostics, CRO services, in-vivo testing, individualized therapy, drug sensitivity testing, patient-derived xenograft, biobank, oncology research, anti-tumor drugs, tumor models, clinical trials support, lifeomics, biomarker discovery, pharmaceutical services, biotech, cancer treatment